1. Home
  2. IVA vs LARK Comparison

IVA vs LARK Comparison

Compare IVA & LARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • LARK
  • Stock Information
  • Founded
  • IVA 2011
  • LARK 1885
  • Country
  • IVA France
  • LARK United States
  • Employees
  • IVA N/A
  • LARK N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • LARK Major Banks
  • Sector
  • IVA Health Care
  • LARK Finance
  • Exchange
  • IVA Nasdaq
  • LARK Nasdaq
  • Market Cap
  • IVA 127.0M
  • LARK 136.3M
  • IPO Year
  • IVA 2020
  • LARK N/A
  • Fundamental
  • Price
  • IVA $2.84
  • LARK $24.11
  • Analyst Decision
  • IVA Strong Buy
  • LARK
  • Analyst Count
  • IVA 4
  • LARK 0
  • Target Price
  • IVA $13.25
  • LARK N/A
  • AVG Volume (30 Days)
  • IVA 10.9K
  • LARK 9.4K
  • Earning Date
  • IVA 03-26-2025
  • LARK 02-04-2025
  • Dividend Yield
  • IVA N/A
  • LARK 3.48%
  • EPS Growth
  • IVA N/A
  • LARK 6.33
  • EPS
  • IVA N/A
  • LARK 2.26
  • Revenue
  • IVA $20,652,523.00
  • LARK $58,168,000.00
  • Revenue This Year
  • IVA N/A
  • LARK N/A
  • Revenue Next Year
  • IVA $197.46
  • LARK N/A
  • P/E Ratio
  • IVA N/A
  • LARK $10.68
  • Revenue Growth
  • IVA N/A
  • LARK 3.55
  • 52 Week Low
  • IVA $1.53
  • LARK $17.05
  • 52 Week High
  • IVA $4.50
  • LARK $26.75
  • Technical
  • Relative Strength Index (RSI)
  • IVA 69.74
  • LARK 46.44
  • Support Level
  • IVA $2.58
  • LARK $24.95
  • Resistance Level
  • IVA $2.80
  • LARK $26.13
  • Average True Range (ATR)
  • IVA 0.15
  • LARK 1.02
  • MACD
  • IVA 0.04
  • LARK -0.02
  • Stochastic Oscillator
  • IVA 81.31
  • LARK 30.89

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The bank is principally engaged in the business of attracting deposits from the general public and using such deposits, together with borrowings and other funds, to originate one-to-four-family residential real estate, construction and land, commercial real estate, commercial, agriculture, municipal and consumer loans. In addition, it also invests in certain investment and mortgage related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.

Share on Social Networks: